Gonadotrophin releasing hormone agonist (buserelin) in the treatment of endometriosis: changes in the extent of the disease and in CA 125 serum levels after 6-month therapy

Marana R, R Marana, Riccardo Marana, L Muzii, L. MUZH, Muzii L, P Muscatello, Muscatello P, Antonio Lanzone, Lanzone A, A Lanzone, Alessandro Caruso, A Caruso, Caruso A, S Dell'Acqua, Dell'Acqua S, Stefano Mancuso, Mancuso S, S Mancuso
British journal of obstetrics and gynaecology · 1990 · vol. 97(11) , pp. 1016–1019 · doi:10.1111/j.1471-0528.1990.tb02474.x · PMID:2147564 · W2057986532
Non-randomised trial OA: closed CC0 ⤵ 7 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Six-month buserelin treatment of endometriosis reduced disease extent and CA 125 levels, but CA 125 did not correlate with disease scores post-treatment, questioning its utility in monitoring therapy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Twenty-two women with endometriosis were treated with the luteinizing hormone-releasing hormone (LHRH) agonist buserelin for 6 months. At second-look laparoscopy the mean score of endometriosis had decreased from 23.1 (SD 17.0) to 17.2 (SD 20.2) (P less than 0.05). CA 125 serum levels decreased from 38.4 (SD 32.2) U/ml at diagnosis to 15.5 (SD 7.0) at second look (P less than 0.005). CA 125 levels correlated at diagnosis with total score of endometriosis (P less than 0.05) and with active score of endometriosis (P less than 0.05), but not with the adhesion score. CA 125 levels were not correlated with endometriosis scores at second look laparoscopy, thus suggesting that mechanisms other than the change in the extent of the disease may be involved in the CA 125 decrease during therapy. CA 125 levels may therefore not be a reliable indicator for monitoring the efficacy of LHRH agonist treatment of endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Antigens, Tumor-Associated, Carbohydrate Biomarkers, Tumor Buserelin Endometriosis Uterine Neoplasms Adult Adult Antigens, Tumor-Associated, Carbohydrate Antigens, Tumor-Associated, Carbohydrate Biomarkers, Tumor Biomarkers, Tumor Buserelin Buserelin Endometriosis Endometriosis Endometriosis Endometriosis Female Female Humans

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (18)

Cited by (7)

SciLite annotations

chemicals 2
buserelin buserelin

Source provenance

europepmc
last seen: 2026-10-10T06:11:15.153948+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:08:55.161857+00:00
scilite
last seen: 2026-05-18T04:57:49.680383+00:00
unpaywall
last seen: 2026-10-10T06:25:47.132674+00:00
License: CC0 · commercial use OK